Modus Therapeutics comments on the start of the first clinical study in the planned sepsis program

Stockholm, Thursday, December 2, 2021. Modus Therapeutics Holding AB ("Modus") announces that the company is set to participate in a live broadcast today at 14:00.

Modus' CEO John Öhd will participate in a live broadcast via Infront Direkt Studios today December 2 at 14:00, to comment on the start of the company's clinical Phase 1b LPS provocation study as communicated in yesterday's published press release.

To follow the live broadcast, click here

For more information on Modus Therapeutics, please contact:

John Öhd, VD, Modus Therapeutics

Telefon: +46 (0) 70 766 80 97

E-post: [email protected]

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: [email protected]

About Modus Therapeutics and sevuparin

Modus Therapeutics is a Swedish biotechnology company headquartered in Stockholm that develops sevuparin with a focus on diseases with a high unmet medical need. The company's focus in the near future is to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal condition. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregate effects.  Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.